Ultragenyx Pharmaceutical | RARE - Cost Of Sales


Ultragenyx Pharmaceutical reported $29M in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
Acadia Pharmaceuticals USD 26.22M 4.58M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Esperion Therapeutics USD 27.85M 13.43M Dec/2025
Insmed USD 46.16M 15.25M Dec/2025
Ionis Pharmaceuticals USD 8M 5.66M Dec/2025
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
Kyowa Hakko Kirin JPY 37.87B 9.67B Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
Ultragenyx Pharmaceutical USD 29M 1.01M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025
Xoma 116K 112.7K Jun/2024